FY2024 EPS Estimates for Immunic Decreased by Analyst

Immunic, Inc. (NASDAQ:IMUX) – Research analysts at Brookline Capital Management reduced their FY2024 earnings per share estimates for shares of Immunic in a report released on Tuesday, October 15th. Brookline Capital Management analyst T. Bussian now expects that the company will earn ($0.89) per share for the year, down from their previous forecast of ($0.87). The consensus estimate for Immunic’s current full-year earnings is ($0.92) per share. Brookline Capital Management also issued estimates for Immunic’s Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.26) EPS and FY2025 earnings at ($1.03) EPS.

Immunic (NASDAQ:IMUX) last issued its earnings results on Thursday, August 8th. The company reported ($0.21) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.02. During the same period last year, the company earned ($0.54) earnings per share.

A number of other equities analysts have also recently issued reports on the company. Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a report on Monday, September 9th. EF Hutton Acquisition Co. I upgraded shares of Immunic to a “strong-buy” rating in a report on Monday, September 16th. StockNews.com upgraded shares of Immunic from a “sell” rating to a “hold” rating in a report on Tuesday, August 13th. Leerink Partners reiterated an “outperform” rating and set a $5.00 price target on shares of Immunic in a research note on Monday, September 9th. Finally, B. Riley started coverage on Immunic in a research note on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price objective for the company. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Immunic currently has a consensus rating of “Buy” and a consensus target price of $11.20.

Immunic Stock Performance

Shares of NASDAQ:IMUX opened at $1.59 on Friday. The firm has a market cap of $143.23 million, a P/E ratio of -0.87 and a beta of 1.84. Immunic has a 52-week low of $0.95 and a 52-week high of $2.11. The business’s 50 day simple moving average is $1.51 and its two-hundred day simple moving average is $1.35.

Institutional Investors Weigh In On Immunic

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in shares of Immunic in the 1st quarter worth approximately $25,000. Ikarian Capital LLC grew its stake in Immunic by 258.3% in the 1st quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after purchasing an additional 1,162,378 shares during the period. Vanguard Group Inc. increased its position in shares of Immunic by 100.7% during the 1st quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares during the last quarter. Janus Henderson Group PLC purchased a new position in shares of Immunic in the 1st quarter worth about $9,266,000. Finally, BVF Inc. IL bought a new position in Immunic during the first quarter valued at about $11,752,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.